Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Good day, and welcome to Arcutis Biotherapeutics 2025 first-quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Osteopath Nick Tofalos has shared a video claiming that one garden weed can be used to treat a variety of ailments, including ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

A fundraiser is coming up to help inform the public about a disease that affects millions of people across the country and ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

The U.S.FDA hasapproved SELARSDI™(ustekinumab-aekn) as interchangeable with the reference biologic Stelara®(ustekinumab) in allpresentations matching the reference product, effective as of April 30, 2 ...